Wedbush Has Positive Outlook for NovoCure FY2026 Earnings

NovoCure Limited (NASDAQ:NVCR) – Research analysts at Wedbush increased their FY2026 EPS estimates for shares of NovoCure in a research note issued on Monday, December 2nd. Wedbush analyst D. Nierengarten now expects that the medical equipment provider will post earnings per share of ($1.14) for the year, up from their previous forecast of ($1.29). Wedbush currently has a “Neutral” rating and a $29.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share. Wedbush also issued estimates for NovoCure’s FY2027 earnings at ($0.88) EPS.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The business had revenue of $155.10 million during the quarter, compared to analysts’ expectations of $143.95 million. During the same period last year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was up 21.8% on a year-over-year basis.

Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target (up from $30.00) on shares of NovoCure in a research note on Monday. Evercore ISI upgraded NovoCure from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $18.00 to $30.00 in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.33.

NovoCure Price Performance

NVCR stock opened at $26.60 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The company’s 50-day moving average is $17.68 and its 200-day moving average is $18.64. The stock has a market capitalization of $2.88 billion, a PE ratio of -19.00 and a beta of 0.75. NovoCure has a 1 year low of $11.66 and a 1 year high of $32.60.

Institutional Trading of NovoCure

A number of hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC purchased a new position in NovoCure in the third quarter valued at about $346,000. Tidal Investments LLC bought a new stake in shares of NovoCure in the 1st quarter worth approximately $695,000. Federated Hermes Inc. raised its holdings in shares of NovoCure by 5.8% in the 2nd quarter. Federated Hermes Inc. now owns 742,927 shares of the medical equipment provider’s stock worth $12,726,000 after purchasing an additional 40,870 shares during the period. Bank of New York Mellon Corp lifted its stake in NovoCure by 56.8% in the second quarter. Bank of New York Mellon Corp now owns 419,960 shares of the medical equipment provider’s stock valued at $7,194,000 after purchasing an additional 152,185 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in NovoCure by 171.9% during the second quarter. Renaissance Technologies LLC now owns 760,175 shares of the medical equipment provider’s stock valued at $13,022,000 after purchasing an additional 480,600 shares during the period. 84.61% of the stock is currently owned by institutional investors.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.